Other languages Alector, Inc.

Equities

ALEC

US0144421072

Market Closed - Nasdaq Other stock markets 01:30:00 30/04/2024 am IST			5-day change	1st Jan Change
5.26 ^USD	+0.19%		+1.74%	-34.09%

17/04	Certain Restricted Stock Units of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	CI
17/04	Certain Options of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alector, Inc. Announces Board Changes	22/03
Alector, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Alector, Inc. Provides Revenue Guidance for the Year Ending 2024	28/02
Alector, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Alector Announces First Patient Dosed in Progress-Ad Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer?S Disease	08/02
Alector, GSK Say FDA Grants Breakthrough Therapy Label For Frontotemporal Dementia Treatment	07/02
GSK : statut de traitement novateur dans la démence	07/02
Alector, Inc. Announces the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation to Latozinemab	07/02
Alector Closes $75 Million Public Stock Offering	19/01
Alector Tumbles After Pricing $75 Million Stock Offering	17/01
Sector Update: Health Care Stocks Decline Pre-Bell Wednesday	17/01
Alector Plans Common Stock Offering; Shares Fall After-Hours	17/01
Alector Shares Rise After Stifel Upgrade	15/12
Alector Insider Sold Shares Worth $132,500, According to a Recent SEC Filing	07/12
Alector, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
Alector, Inc. Reiterates Earnings Guidance for the Year Ending 2023	08/11
Sector Update: Health Care Stocks Gain Premarket Monday	30/23/30
Alector Reaches Enrollment Target for Latozinemab Phase 3 Trial	28/23/28
Alector, Inc. Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to Progranulin Gene Mutation (FTD-GRN)	27/23/27
Alector Insider Sold Shares Worth $3,000,000, According to a Recent SEC Filing	14/23/14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Alector, Inc.

Equities

ALEC

US0144421072

Other languages

Filters